

Title (en)
EGFR AND PAR2 REGULATION OF INTESTINAL PERMEABILITY

Title (de)
EGFR- UND PAR2-REGULIERUNG DER DARMDURCHLÄSSIGKEIT

Title (fr)
RÉGULATION PAR EGFR ET PAR2 DE LA PERMÉABILITÉ INTESTINALES

Publication
EP 2440246 A4 20130828 (EN)

Application
EP 10786502 A 20100610

Priority

- US 2010001670 W 20100610
- US 18566209 P 20090610

Abstract (en)
[origin: WO2010144140A2] The present invention provides a method of treating an autoimmune disease, comprising the steps of increasing transepithelial electrical resistance leading to decreased cell permeability. Further provided is a method of treating celiac disease in an individual in need of such treatment, comprising the steps of: administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting PAR2.

IPC 8 full level
A61K 39/395 (2006.01); **A61K 31/7105** (2006.01); **A61P 1/04** (2006.01); **A61P 3/10** (2006.01); **A61P 37/00** (2006.01)

CPC (source: EP KR)
A61K 31/7105 (2013.01 - EP); **A61K 39/3955** (2013.01 - KR); **A61K 48/005** (2013.01 - KR); **A61K 48/0058** (2013.01 - KR); **A61P 1/00** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/12** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61K 2121/00** (2013.01 - KR)

Citation (search report)

- [X] SAPONE A ET AL: "Inhibition of the zonulin pathway blocks the progression from pre-clinical autoimmunity to type 1 diabetes in BB/Wor rats", DIGESTIVE AND LIVER DISEASE, W.B. SAUNDERS, GB, vol. 38, 1 April 2006 (2006-04-01), pages S87 - S87, XP025948595, ISSN: 1590-8658, [retrieved on 20060401], DOI: 10.1016/S1590-8658(06)80231-8
- [X] "AGA Abstracts S1448-M1084", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 126, no. 4, 1 April 2004 (2004-04-01), pages A249 - A249, XP022471374, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(04)80010-6
- [X] M C ARRIETA ET AL: "Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse", GUT, vol. 58, no. 1, 1 October 2008 (2008-10-01), pages 41 - 48, XP055071471, ISSN: 0017-5749, DOI: 10.1136/gut.2008.150888
- [I] SMECUOL ET AL: "Permeability, zonulin production, and enteropathy in dermatitis herpetiformis", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL ASSOCIATION, US, vol. 3, no. 4, 1 April 2005 (2005-04-01), pages 335 - 341, XP005120726, ISSN: 1542-3565, DOI: 10.1016/S1542-3565(04)00778-5
- [I] SAPONE A ET AL: "Serum zonulin and intestinal permeability before and after a gluten-containing meal in both type 1 diabetes and their relatives", DIGESTIVE AND LIVER DISEASE, W.B. SAUNDERS, GB, vol. 38, 1 April 2006 (2006-04-01), pages S75 - S75, XP025948561, ISSN: 1590-8658, [retrieved on 20060401], DOI: 10.1016/S1590-8658(06)80197-0
- See references of WO 2010144140A2

Citation (examination)

- US 2006040883 A1 20060223 - YOU LIANG [US], et al
- SANDRO DRAGO ET AL: "Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 41, no. 4, 1 January 2006 (2006-01-01), pages 408 - 419, XP055105654, ISSN: 0036-5521, DOI: 10.1080/00365520500235334
- PAPP M. ET AL: "Haptoglobin Polymorphism: A Novel Genetic Risk Factor for Celiac Disease Development and Its Clinical Manifestations", CLINICAL CHEMISTRY, vol. 54, no. 4, 1 April 2008 (2008-04-01), pages 697 - 704, XP055105643, ISSN: 0009-9147, DOI: 10.1373/clinchem.2007.098780
- PAPP M. ET AL: "S1256 Haptoglobin Polymorphism: A Novel Genetic Risk Factor for Celiac Disease Development and Its Clinical Manifestations", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 134, no. 4, 1 April 2008 (2008-04-01), pages A-211 - A-212, XP023432775, ISSN: 0016-5085, [retrieved on 20080401], DOI: 10.1016/S0016-5085(08)60978-6
- SAGIV E ET AL: "992 Unraveling Novel Mechanisms By Which the CD24 Oncogene Serves As a Target for Colorectal and Pancreatic Cancer Treatment, Via Down-Regulation By Monoclonal Antibodies or SIRNA", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 134, no. 4, 1 April 2008 (2008-04-01), pages A - 149, XP023432489, ISSN: 0016-5085, [retrieved on 20080401], DOI: 10.1016/S0016-5085(08)60692-7

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)
WO 2010144140 A2 20101216; WO 2010144140 A3 20110519; WO 2010144140 A4 20110714; WO 2010144140 A8 20120126;
AU 2010259213 A1 20120119; CA 2765075 A1 20101216; CN 102481362 A 20120530; CN 104940927 A 20150930; EP 2440246 A2 20120418; EP 2440246 A4 20130828; JP 2012529508 A 20121122; KR 20120031496 A 20120403

DOCDB simple family (application)
US 2010001670 W 20100610; AU 2010259213 A 20100610; CA 2765075 A 20100610; CN 201080031880 A 20100610; CN 201510201412 A 20100610; EP 10786502 A 20100610; JP 2012514946 A 20100610; KR 20127000353 A 20100610